Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

OVER-MYR

Financiado

Cerrado

Overcoming clinical relapse in multiple myeloma by understanding and targeting t...

Overcoming clinical relapse in multiple myeloma by understanding and targeting the molecular causes of drug resistance Multiple Myeloma (MM) is a currently incurable rare malignant plasma cell disease, which invariably relapses despite therapy. The objective of OVER-MYR is to understand the causes of drug resistance and relapse, develop novel stra... ver más

30/06/2015

VUB

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

VRIJE UNIVERSITEIT BRUSSEL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 8 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2015-06-30 No tenemos la información de la convocatoria

0% 76% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

8 Participantes

VUB

0.00€ | Lider

Academisch Medisch Centrum A...

N.D. | Participante

INSERM TRANSFERT SA

N.D. | Participante

SOUTHAMPTON

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

OPTATIO OPtimizing TArgets and Therapeutics In high risk and refract... 4M€ Cerrado

CombaTCancer Rational combination therapies for metastatic cancer 2M€ Cerrado

RESISTANCEPROGRAMS Tumor recurrence and therapeutic resistance: exploring and e... 2M€ Cerrado

ChAMPioN Game changing Precision Medicine for Curing All Myeloprolife... 3M€ Cerrado

PID2020-114638RA-I00 MECANISMOS MOLECULARES DE LA RESISTENCIA A TERAPIA Y PLASTIC... 229K€ Cerrado

CMLMULTIHIT Establishment of a novel CML model using Multi Hit technolog... 171K€ Cerrado

Líder del proyecto

VRIJE UNIVERSITEIT BRUSSEL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Multiple Myeloma (MM) is a currently incurable rare malignant plasma cell disease, which invariably relapses despite therapy. The objective of OVER-MYR is to understand the causes of drug resistance and relapse, develop novel strategies to overcome these, provide proof of principal for phase I/II trial, and thus impact on MM-patient’s survival.Currently-used drugs target both MM cells (MMC) and cells of the bone marrow (BM) microenvironment or ‘niche’ that are critical for supporting MMC survival, proliferation and growth. Since patients repeatedly relapse after such treatments, the following mechanisms of relapse are considered and need to be investigated: i) drugs have spared specific subclones or subpopulations of MMC ii) drugs induce alterations in cells of the ‘niche’ that promote drug-resistance. OVER-MYR integrates a network of outstanding researchers from 6 EU countries with internationally recognized experience in clinics and human and animal models of MM, who will jointly: WP1: Study the molecular alterations in primary MM and environment cells in samples obtained from a large number of patients at treatment inclusion and relapse, using high throughput techniques. WP2: Implement in vitro and in vivo models of drug resistance to evaluate molecular and cellular mechanisms and compare their characteristics with drug resistant cells isolated from patients. Combined results of WP1 and WP2 will permit the identification of 10 prominent (altered) candidate genes involved in MM relapse. Changes in drug resistance, cell survival and proliferation will be assessed in WP2 by modulating the expression of the selected genes. WP3: Determine how cells from the niche alter their functions in the presence of drugs, and how drug-altered cells impact on MM cells during therapy. WP4: Screen chemical libraries for drugs active on generated sensitive cell lines, develop innovative inhibitors and provide proof of principle for a phase I/II trial

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores